151. Identification of novel mutations and risk assessment of Han Chinese patients with autosomal dominant polycystic kidney disease
- Author
-
Mingchao Zhang, Shuaimei Liu, Xin-Yi Xia, Ying-Xia Cui, and Xiao-Jun Li
- Subjects
Adult ,Male ,China ,Heredity ,TRPP Cation Channels ,Time Factors ,Genetic counseling ,DNA Mutational Analysis ,Nonsense mutation ,030232 urology & nephrology ,Autosomal dominant polycystic kidney disease ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,Risk Assessment ,Frameshift mutation ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,Risk Factors ,Genotype ,medicine ,Humans ,Genetic Predisposition to Disease ,Allele ,Genetic Association Studies ,Genetics ,PKD1 ,urogenital system ,business.industry ,High-Throughput Nucleotide Sequencing ,General Medicine ,Middle Aged ,Polycystic Kidney, Autosomal Dominant ,Prognosis ,medicine.disease ,female genital diseases and pregnancy complications ,Pedigree ,Phenotype ,Nephrology ,Mutation ,Disease Progression ,Mutation testing ,Kidney Failure, Chronic ,Female ,business ,Multiplex Polymerase Chain Reaction - Abstract
Aim Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease in humans and is caused by mutations in the PKD1 or PKD2 gene. ADPKD is heterogeneous with regard to locus and allele heterogeneity and phenotypic variability. Methods Using targeted capture associated with next generation sequencing (NGS), we performed a mutational analysis of Han Chinese patients with ADPKD from 62 unrelated families. Multivariate Cox proportional hazard modelling of their different clinical characteristics and mutation classes was performed. Results The detection rate for a PKD1 and PKD2 mutation in the Chinese ADPKD patients was 95.2% (59/62). We identified pathogenic mutations in 64.4% (38/59) of patients, including 32PKD1 mutations (15 nonsense mutations, 15 frameshift mutation, one splice mutation, and one large deletion) and six PKD2 mutations (three nonsense mutations and three frameshift mutations). Of the pathogenic variants we identified, 50% (19/38) were novel variants and 50% (19/38) were known variants. Patients with PKD2 mutations had milder and indistinguishable phenotypes. Significant phenotypic differences were observed among the various types of PKD1 mutations. Conclusion Our results show that targeted capture associated with next-generation sequencing is an effective strategy for genetically testing ADPKD patients. This mutation analysis of ADPKD in Han Chinese extends our understanding of the genetic diversity of different ethnic groups, enriches the mutation database, and contributes to the genetic counselling of ADPKD patients.
- Published
- 2019